由“仿”到“创” 中国医药迈步康庄大道

中国新闻网
08 Mar

中新网北京3月8日电 “最近,一家名不见经传的中国企业生产的新药击败了全世界最畅销的抗癌药。”  全国政协委员、中国医学科学院肿瘤医院主任医师赵宏在全国政协十四届三次会议首场“委员通道”上分享了一则令人振奋的消息。  中国新闻网中新健康了解到,创造这一成绩的中国药企是康方生物。  其研发的PD-1/VEGF双特异性抗体药物依沃西单抗(产品名:依达方®),在去年一项“单药头对头试验”中战胜了全球畅销...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10